Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Small-molecule agents for the treatment of inflammatory bowel disease.

Currie KS, Patel L, Sedillo KF.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2034-2041. doi: 10.1016/j.bmcl.2019.06.042. Epub 2019 Jun 25. Review.

PMID:
31266686
2.

Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis.

Clarke AS, Rousseau E, Wang K, Kim JY, Murray BP, Bannister R, Matzkies F, Currie KS, Di Paolo JA.

Thromb Res. 2018 Oct;170:109-118. doi: 10.1016/j.thromres.2018.08.012. Epub 2018 Aug 23.

PMID:
30172129
3.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.

Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, DiPaolo J, Reif K, Scheerens H, Schmitt A, Wong H, Xiong JM, Xu J, Zhao Z, Zhou F, Currie KS, Young WB.

ACS Med Chem Lett. 2017 May 3;8(6):608-613. doi: 10.1021/acsmedchemlett.7b00103. eCollection 2017 Jun 8.

4.

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

Katewa A, Wang Y, Hackney JA, Huang T, Suto E, Ramamoorthi N, Austin CD, Bremer M, Chen JZ, Crawford JJ, Currie KS, Blomgren P, DeVoss J, DiPaolo JA, Hau J, Johnson A, Lesch J, DeForge LE, Lin Z, Liimatta M, Lubach JW, McVay S, Modrusan Z, Nguyen A, Poon C, Wang J, Liu L, Lee WP, Wong H, Young WB, Townsend MJ, Reif K.

JCI Insight. 2017 Apr 6;2(7):e90111. doi: 10.1172/jci.insight.90111.

5.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Eigenbrot C, Gallion S, Johnson AR, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Wang X, Wong H, Xiong JM, Xu J, Yu C, Zhao Z, Currie KS.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):575-579. doi: 10.1016/j.bmcl.2015.11.076. Epub 2015 Nov 24.

PMID:
26675441
6.

Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Gallion S, Hymowitz SG, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Maurer B, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Sowell CG, Wang X, Wong H, Xiong JM, Xu J, Zhao Z, Currie KS.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1333-7. doi: 10.1016/j.bmcl.2015.01.032. Epub 2015 Feb 7.

PMID:
25701252
7.

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.

Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, Gallion S, Whitney JA, Maclin D, Lansdon EB, Maciejewski P, Rossi AM, Rong H, Macaluso J, Barbosa J, Di Paolo JA, Mitchell SA.

J Med Chem. 2014 May 8;57(9):3856-73. doi: 10.1021/jm500228a. Epub 2014 Apr 29.

PMID:
24779514
8.

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.

Oncotarget. 2014 Feb 28;5(4):908-15.

9.

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.

Liu L, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, Boggs J, Kuebler P, Davis JC Jr, Liao XC, Lubach JW, Deese A, Sowell CG, Currie KS, Young WB, Khojasteh SC, Hop CE, Wong H.

Drug Metab Dispos. 2011 Oct;39(10):1840-9. doi: 10.1124/dmd.111.040840. Epub 2011 Jul 8.

PMID:
21742900
10.

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS.

Nat Chem Biol. 2011 Jan;7(1):41-50. doi: 10.1038/nchembio.481. Epub 2010 Nov 28.

PMID:
21113169
11.

Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.

Mitchell SA, Danca MD, Blomgren PA, Darrow JW, Currie KS, Kropf JE, Lee SH, Gallion SL, Xiong JM, Pippin DA, DeSimone RW, Brittelli DR, Eustice DC, Bourret A, Hill-Drzewi M, Maciejewski PM, Elkin LL.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6991-5. doi: 10.1016/j.bmcl.2009.10.037. Epub 2009 Oct 15.

PMID:
19879134
12.

Privileged structures: applications in drug discovery.

DeSimone RW, Currie KS, Mitchell SA, Darrow JW, Pippin DA.

Comb Chem High Throughput Screen. 2004 Aug;7(5):473-94. Review.

PMID:
15320713

Supplemental Content

Loading ...
Support Center